Li Watsek

Stock Analyst at Cantor Fitzgerald

(0)
# 4747
Out of 5,441 analysts
97
Total ratings
Success rate
Average return
Main Sectors:
Top Industries:
23 Stocks
Name Action PT Current % Upside Ratings Updated
ASND Ascendis Pharma
Maintains: Overweight
200 203
195.94 3.6% 19 Aug 8, 2025
REPL Replimune Group
Upgrades: Overweight
n/a
n/a n/a 2 Jul 30, 2025
KURA Kura Oncology
Reiterates: Overweight
n/a
n/a n/a 11 Jun 26, 2025
ZLAB Zai Lab
Reiterates: Overweight
n/a
n/a n/a 1 Mar 27, 2025
ACRV Acrivon Therapeutics
Reiterates: Overweight
n/a
n/a n/a 2 Mar 26, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
n/a
n/a n/a 1 Mar 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 5 Feb 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 7 Jan 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 2 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 7 Nov 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 4 Oct 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
20 20
8.52 134.74% 2 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 5 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 1 May 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 5 Apr 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 5 Apr 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
3
1.53 96.08% 4 Nov 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
220
8.87 2380.27% 3 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
26
0.53 4805.66% 3 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
5
0.94 431.91% 3 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
1140
1.71 66566.67% 2 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
60 38
2 1800% 1 Aug 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
75 69
n/a n/a 2 Aug 9, 2022